There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Dornase alfa is currently used as a mucolytic to treat pulmonary disease (the major
cause of morbidity and mortality) in cystic fibrosis. It reduces mucus viscosity in
the lungs, promoting improved clearance of secretions. This is an update of a previously
published review.